Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
Background and aimsDespite proven clinical efficacy of vedolizumab (VDZ) for inducing and maintaining remission in patients with Crohn’s disease (CD) and ulcerative colitis (UC), subgroups of patients have no therapeutic benefit from anti-α4β7 integrin therapy with VDZ. Within this study, we aimed t...
Na minha lista:
| Principais autores: | , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2018-07-01
|
| Serier: | Frontiers in Immunology |
| Fag: | |
| Online adgang: | https://www.frontiersin.org/article/10.3389/fimmu.2018.01700/full |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|